person · Reporting owner
Fenimore Christopher R.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | EVP Finance CFO | August 18, 2026 | August 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENERON PHARMACEUTICALS, INC.
Report date August 18, 2026 · Filed August 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,984 |
Ending reported balance
After 2026-08-18 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-18 · Exercise / conversion · Acquired 6,283 · Balance 24,583 Row 2 · 2026-08-18 · Tax withholding · Disposed 4,599 · Balance 19,984 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $381.92 · Expires 2026-12-16 | Direct | 6,000 |
Reported balance
After 2026-08-18 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-08-18 · Exercise / conversion · Disposed 6,283 · Balance 6,000 F2: The stock option award vested in four equal annual installments, commencing one year after the date of grant. |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) Plan | 1,574 |
Reported balance
Holding disclosure · report date 2026-08-18 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,574 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 1,897 |
Reported balance
Holding disclosure · report date 2026-08-18 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 1,897 F1: These shares are held in a trust for the benefit of the reporting person's spouse. The reporting person and the reporting person's spouse are trustees of the trust. |
| Common StockSEC Table I · non-derivative | Indirectby Trust for Daugh | 25 |
Reported balance
Holding disclosure · report date 2026-08-18 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 25 |
| Common StockSEC Table I · non-derivative | Indirectby Trust for Son | 25 |
Reported balance
Holding disclosure · report date 2026-08-18 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 25 |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are held in a trust for the benefit of the reporting person's spouse. The reporting person and the reporting person's spouse are trustees of the trust.
F2: The stock option award vested in four equal annual installments, commencing one year after the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 20, 2019 Filed Dec 23, 2019 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 400 | $30.63 | $12,252.00 |
DisclosureSEC source: 0001708138-19-000014 · edgardoc.xml · nonDerivative · entry 1 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,597 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 13, 2019 Filed Dec 13, 2019 23:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 51 | $378.27 | $19,291.77 |
DisclosureSEC source: 0001237899-19-000038 · edgardoc.xml · nonDerivative · entry 9 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,197 F3 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 13, 2019 Filed Dec 13, 2019 23:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 346 | $377.38 | $130,573.48 |
DisclosureSEC source: 0001237899-19-000038 · edgardoc.xml · nonDerivative · entry 8 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,248 F3 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 346 shares of Company stock on December 13, 2019 at prices ranging from $377.09 to $377.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 13, 2019 at each separate price. Read SEC document |
| December 13, 2019 Filed Dec 13, 2019 23:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 470 | $376.27 | $176,846.90 |
DisclosureSEC source: 0001237899-19-000038 · edgardoc.xml · nonDerivative · entry 7 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,594 F3 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 470 shares of Company stock on December 13, 2019 at prices ranging from $376.02 to $376.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 13, 2019 at each separate price. Read SEC document |
| December 13, 2019 Filed Dec 13, 2019 23:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 624 | $375.58 | $234,361.92 |
DisclosureSEC source: 0001237899-19-000038 · edgardoc.xml · nonDerivative · entry 6 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,064 F3 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 624 shares of Company stock on December 13, 2019 at prices ranging from $375.05 to $375.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 13, 2019 at each separate price. Read SEC document |
| December 13, 2019 Filed Dec 13, 2019 23:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 191 | $374.82 | $71,590.62 |
DisclosureSEC source: 0001237899-19-000038 · edgardoc.xml · nonDerivative · entry 5 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,688 F3 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 191 shares of Company stock on December 13, 2019 at prices ranging from $374.65 to $374.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 13, 2019 at each separate price. Read SEC document |
| December 12, 2019 Filed Dec 13, 2019 23:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,100 | $0.00 Strike: $52.03 | $0.00 |
DisclosureSEC source: 0001237899-19-000038 · edgardoc.xml · derivative · entry 14 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,226 Underlying: Common Stock · 3,100 shares Expires 2021-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F9 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 12, 2019 Filed Dec 13, 2019 23:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 1,418 | $377.16 | $534,812.88 |
DisclosureSEC source: 0001237899-19-000038 · edgardoc.xml · nonDerivative · entry 4 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,879 F3 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 12, 2019 Filed Dec 13, 2019 23:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 3,100 | $52.03 | $161,293.00 |
DisclosureSEC source: 0001237899-19-000038 · edgardoc.xml · nonDerivative · entry 3 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,297 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 11, 2019 Filed Dec 13, 2019 23:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 6,120 | $0.00 Strike: $372.46 | $0.00 |
DisclosureSEC source: 0001237899-19-000038 · edgardoc.xml · derivative · entry 15 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,120 Underlying: Common Stock · 6,120 shares Expires 2029-12-11 F9 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 11, 2019 Filed Dec 13, 2019 23:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-19-000038 · edgardoc.xml · nonDerivative · entry 2 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,197 F2 · kind: Award of Restricted Stock under the Amended and Restated 2014 Long-Term Incentive Plan that vests in its entirety on December 11, 2023. Read SEC document |
| December 11, 2019 Filed Dec 13, 2019 23:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 1,020 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-19-000038 · edgardoc.xml · nonDerivative · entry 1 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,697 F1 · kind: Award of Restricted Stock under the Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 11, 2021 and 50% on December 11, 2023. Read SEC document |
| April 18, 2019 Filed Apr 18, 2019 23:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 350 | $0.00 Strike: $21.25 | $0.00 |
DisclosureSEC source: 0001237899-19-000011 · edgardoc.xml · derivative · entry 7 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 350 shares Expires 2019-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| April 18, 2019 Filed Apr 18, 2019 23:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 350 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-19-000011 · edgardoc.xml · nonDerivative · entry 3 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 1,897 F1 · ownership.nature: These shares are held in a trust for the benefit of the reporting person's spouse. The reporting person and the reporting person's spouse are trustees of the trust. Read SEC document |
| April 18, 2019 Filed Apr 18, 2019 23:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 350 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-19-000011 · edgardoc.xml · nonDerivative · entry 2 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,096 Read SEC document |
| April 18, 2019 Filed Apr 18, 2019 23:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 350 | $21.25 | $7,437.50 |
DisclosureSEC source: 0001237899-19-000011 · edgardoc.xml · nonDerivative · entry 1 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,446 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 18, 2019 Filed Jan 18, 2019 22:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 150 | $0.00 Strike: $21.25 | $0.00 |
DisclosureSEC source: 0001237899-19-000008 · edgardoc.xml · derivative · entry 7 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350 Underlying: Common Stock · 150 shares Expires 2019-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| January 18, 2019 Filed Jan 18, 2019 22:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 150 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-19-000008 · edgardoc.xml · nonDerivative · entry 3 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 1,547 F1 · ownership.nature: These shares are held in a trust for the benefit of the reporting person's spouse. The reporting person and the reporting person's spouse are trustees of the trust. Read SEC document |
| January 18, 2019 Filed Jan 18, 2019 22:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 150 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-19-000008 · edgardoc.xml · nonDerivative · entry 2 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,096 Read SEC document |
| January 18, 2019 Filed Jan 18, 2019 22:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 150 | $21.25 | $3,187.50 |
DisclosureSEC source: 0001237899-19-000008 · edgardoc.xml · nonDerivative · entry 1 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,246 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 20, 2018 Filed Dec 20, 2018 22:36 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 675 | $0.00 Strike: $21.25 | $0.00 |
DisclosureSEC source: 0001237899-18-000026 · edgardoc.xml · derivative · entry 16 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 Underlying: Common Stock · 675 shares Expires 2019-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 20, 2018 Filed Dec 20, 2018 22:36 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 200 | $362.45 | $72,490.00 |
DisclosureSEC source: 0001237899-18-000026 · edgardoc.xml · nonDerivative · entry 11 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,096 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 200 shares of Company stock on December 20, 2018 at prices ranging from $362.02 to $362.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 20, 2018 at each separate price. Read SEC document |
| December 20, 2018 Filed Dec 20, 2018 22:36 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $361.65 | $36,165.00 |
DisclosureSEC source: 0001237899-18-000026 · edgardoc.xml · nonDerivative · entry 10 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,296 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 20, 2018 Filed Dec 20, 2018 22:36 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 500 | $360.40 | $180,200.00 |
DisclosureSEC source: 0001237899-18-000026 · edgardoc.xml · nonDerivative · entry 9 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,396 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 500 shares of Company stock on December 20, 2018 at prices ranging from $360.18 to $360.72. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 20, 2018 at each separate price. Read SEC document |
| December 20, 2018 Filed Dec 20, 2018 22:36 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 200 | $359.38 | $71,876.00 |
DisclosureSEC source: 0001237899-18-000026 · edgardoc.xml · nonDerivative · entry 8 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,896 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 200 shares of Company stock on December 20, 2018 at prices ranging from $359.18 to $359.57. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 2018 at each separate price. Read SEC document |
| December 20, 2018 Filed Dec 20, 2018 22:36 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 200 | $358.27 | $71,654.00 |
DisclosureSEC source: 0001237899-18-000026 · edgardoc.xml · nonDerivative · entry 7 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,096 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 200 shares of Company stock on December 20, 2018 at prices ranging from $358.18 to $358.35. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 20, 2018 at each separate price. Read SEC document |
| December 20, 2018 Filed Dec 20, 2018 22:36 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 200 | $357.50 | $71,500.00 |
DisclosureSEC source: 0001237899-18-000026 · edgardoc.xml · nonDerivative · entry 6 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,296 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 200 shares of Company stock on December 20, 2018 at prices ranging from $357.15 to $357.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 20, 2018 at each separate price. Read SEC document |
| December 20, 2018 Filed Dec 20, 2018 22:36 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 348 | $356.27 | $123,981.96 |
DisclosureSEC source: 0001237899-18-000026 · edgardoc.xml · nonDerivative · entry 5 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,496 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 348 shares of Company stock on December 20, 2018 at prices ranging from $356.22 to $356.34. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 20, 2018 at each separate price. Read SEC document |
| December 20, 2018 Filed Dec 20, 2018 22:36 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $355.14 | $35,514.00 |
DisclosureSEC source: 0001237899-18-000026 · edgardoc.xml · nonDerivative · entry 4 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,844 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 20, 2018 Filed Dec 20, 2018 22:36 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 675 | $21.25 | $14,343.75 |
DisclosureSEC source: 0001237899-18-000026 · edgardoc.xml · nonDerivative · entry 3 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,944 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 19, 2018 Filed Dec 20, 2018 22:36 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,450 | $0.00 Strike: $52.03 | $0.00 |
DisclosureSEC source: 0001237899-18-000026 · edgardoc.xml · derivative · entry 17 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,326 Underlying: Common Stock · 3,450 shares Expires 2021-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F9 · derivative.exercise_date: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 19, 2018 Filed Dec 20, 2018 22:36 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 1,602 | $364.42 | $583,800.84 |
DisclosureSEC source: 0001237899-18-000026 · edgardoc.xml · nonDerivative · entry 2 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,269 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 19, 2018 Filed Dec 20, 2018 22:36 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 3,450 | $52.03 | $179,503.50 |
DisclosureSEC source: 0001237899-18-000026 · edgardoc.xml · nonDerivative · entry 1 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,871 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 12, 2018 Filed Dec 14, 2018 21:18 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 11,400 | $0.00 Strike: $381.40 | $0.00 |
DisclosureSEC source: 0001237899-18-000021 · edgardoc.xml · derivative · entry 8 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,400 Underlying: Common Stock · 11,400 shares Expires 2028-12-12 F3 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 12, 2018 Filed Dec 14, 2018 21:18 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-18-000021 · edgardoc.xml · nonDerivative · entry 2 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,421 F1 · kind: Award of Restricted Stock under the Amended and Restated 2014 Long-Term Incentive Plan that vests in its entirety on December 12, 2023. Read SEC document |
| October 25, 2018 Filed Dec 14, 2018 21:18 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 2,950 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-18-000021 · edgardoc.xml · nonDerivative · entry 5 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Indirect · by 2018 GRAT Disclosed balance after: 2,950 Read SEC document |
| October 25, 2018 Filed Dec 14, 2018 21:18 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 2,950 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-18-000021 · edgardoc.xml · nonDerivative · entry 4 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 1,397 F2 · ownership.nature: These shares are held in a trust for the benefit of the reporting person's spouse. The reporting person and the reporting person's spouse are trustees of the trust. Read SEC document |
| August 30, 2018 Filed Aug 31, 2018 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 50 | $0.00 Strike: $21.25 | $0.00 |
DisclosureSEC source: 0001708138-18-000019 · edgardoc.xml · derivative · entry 5 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,175 Underlying: Common Stock · 50 shares Expires 2019-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| August 30, 2018 Filed Aug 31, 2018 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 50 | $21.25 | $1,062.50 |
DisclosureSEC source: 0001708138-18-000019 · edgardoc.xml · nonDerivative · entry 1 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 30, 2018 Filed Dec 14, 2018 21:18 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 50 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-18-000021 · edgardoc.xml · nonDerivative · entry 3 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 4,347 F2 · ownership.nature: These shares are held in a trust for the benefit of the reporting person's spouse. The reporting person and the reporting person's spouse are trustees of the trust. Read SEC document |
| August 30, 2018 Filed Dec 14, 2018 21:18 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 50 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-18-000021 · edgardoc.xml · nonDerivative · entry 1 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,421 Read SEC document |
| January 16, 2018 Filed Jan 17, 2018 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 150 | $0.00 Strike: $21.25 | $0.00 |
DisclosureSEC source: 0001237899-18-000007 · edgardoc.xml · derivative · entry 5 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,225 Underlying: Common Stock · 150 shares Expires 2019-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| January 16, 2018 Filed Jan 17, 2018 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 150 | $21.25 | $3,187.50 |
DisclosureSEC source: 0001237899-18-000007 · edgardoc.xml · nonDerivative · entry 1 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 12, 2017 Filed Dec 13, 2017 21:53 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 12,300 | $0.00 Strike: $378.98 | $0.00 |
DisclosureSEC source: 0001237899-17-000030 · edgardoc.xml · derivative · entry 1 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,300 Underlying: Common Stock · 12,300 shares Expires 2027-12-12 F1 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.